New cocktail of drugs shows promise for Tough-to-Treat colorectal cancer
NCT ID NCT07491159
First seen Mar 28, 2026 · Last updated Jun 22, 2026 · Updated 15 times
Summary
This study tests a combination of three drugs—fruquintinib (targeted therapy), an immune checkpoint inhibitor (immunotherapy), and TAS-102 (oral chemotherapy)—in people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this mix can shrink tumors and help patients live longer. About 106 participants will be enrolled at one center in China.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, 300202, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fruquintinib, immune checkpoint inhibitor, and trifluridine/tipiracil (TAS-102)
What this could lead to
If successful, this could provide a new treatment option for patients with advanced colorectal cancer who have few choices left, potentially extending survival.
What could go wrong
This is an early-phase (Ib/II) study with only 106 participants, so results may not apply broadly. Combining multiple drugs also raises the risk of side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.